



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-063001	Application No. 10/086,217
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Mundy <i>et al.</i>	
		Filing Date February 21, 2002	Group Art Unit 1644

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	BA	5,217,870	06/08/1993	Hession <i>et al.</i>			
	BB	5,272,263	12/21/1993	Hession <i>et al.</i>			
	BC	5,367,056	11/22/1994	Hession <i>et al.</i>			
	BD	5,695,755	12/09/1997	Papayannopoulou			
	BE	5,824,304	10/20/1998	Papayannopoulou			
	BF	5,843,438	12/01/1998	Papayannopoulou			
	BG	5,871,734	02/16/1999	Lobb <i>et al.</i>			
	BH	5,888,507	03/30/1999	Burkly			
	BI	5,932,214	08/03/1999	Lobb <i>et al.</i>			
	BJ	6,252,043	06/26/2001	Hession <i>et al.</i>			
	BK	6,307,025	10/23/2001	Hession <i>et al.</i>			
	BL	6,602,503	08/05/2003	Lobb <i>et al.</i>			
	BM						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	BN	WO 90/13300	11/15/1990	WIPO				
	BO	WO 93/13798	07/22/1993	WIPO				
	BP	WO 93/15764	08/19/1993	WIPO				
	BQ	WO 94/11027	05/26/1994	WIPO				
	BR	WO 94/16094	07/21/1994	WIPO				
	BS	WO 94/17828	08/18/1994	WIPO				
	BT							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	BU	Chevalier <i>et al.</i> , "Interleukin-6 Family of Cytokines Induced Activation of Different Functional Sites Expressed by gp130 Transducing Protein," <i>J. Biol. Chem.</i> 271:14764-14772, 1996.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10274-063001	Application No. 10/086,217
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Mundy <i>et al.</i>	
		Filing Date February 21, 2002	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	BV	Hemler <i>et al.</i> , "Characterization of the Cell Surface Heterodimer VLA-4 and Related Peptides," <i>J. Biol. Chem.</i> 262:11478-11485, 1987.
	BW	Mori <i>et al.</i> , "Anti- α 4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis," <i>Blood</i> 104:2149-2154, 2004.
	BX	Pulido <i>et al.</i> , "Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4," <i>J. Biol. Chem.</i> 266:10241-10245, 1991.
	BY	Sanchez-Madrid <i>et al.</i> , "VLA-3: A novel polypeptide association within the VLA molecular complex: cell distribution and biochemical characterization," <i>Eur. J. Immunol.</i> 16:1343-1349, 1986.
	BZ	Schwabe <i>et al.</i> , "Differential Expression and Ligand-induced Modulation of the Human Interleukin-6 Receptor on Interleukin-6-responsive Cells," <i>J. Biol. Chem.</i> 269:7201-7209, 1994.

Examiner Signature	/Maher Haddad/	Date Considered	03/06/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			